Skip to main content
. Author manuscript; available in PMC: 2017 Jun 18.
Published in final edited form as: Lancet Oncol. 2016 Jun 4;17(7):943–955. doi: 10.1016/S1470-2045(16)30126-7

Figure 4. Overall survival.

Figure 4

HR=hazard ratio. NR=not reached. *Median follow-up in the nivolumab followed by ipilimumab group was 19·8 months (IQR 12·8–257). †Median follow-up in the ipilimumab followed by nivolumab group was 147 months (56–23·9).